VERV

Verve Therapeutics

VERV

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)50%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Verve Therapeutics, Inc.

Location

Verve Therapeutics

VERV

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)50%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about VERV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Jun 18

Eli Lilly's acquisition of Verve Therapeutics, Inc. (VERV) has put the spotlight on other gene therapy companies, including VERVE-102, an investigational therapy aimed at reducing cholesterol levels.
Verve Therapeutics' (VERV) shares have been impacted by the acquisition, with some analysts setting a target price of $13.5, while others have adjusted their rating to Hold.
The acquisition has sparked discussions about the potential for a short squeeze in Verve Therapeutics' (VERV) shares, with some analysts suggesting that the company's shares may be undervalued compared to its peers.

Generated by AI

Sentiment

Of the messages about VERV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	86.81% +0.06
Bearish	—	0%	0% 0	13.19% -0.06

Bullish· Jun 17

$VERV is likely to be acquired, potentially for a price that would result in a significant increase in its market value, with some predictions as high as $10 billion.
The upcoming data from Verve Therapeutics could attract strategic interest, potentially leading to a buyout or acquisition.
$VERV has a game-changing pipeline for heart disease, which could lead to significant growth and value creation for the company.

Bearish· Jun 17

The acquisition price of $1.3 billion may be too low, with some investors demanding at least $3 billion in cash.
The deal may have been undervalued, with some investors believing the company is worth $25 per share.
The acquisition may have been negotiated with insider interests in mind, potentially leaving other shareholders with lower returns.

Generated by AI

Topics

Of the messages about VERV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	1.83%
Announcements	—	—	100%	92.93%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	5.24%

Jun 17

Eli Lilly agreed to acquire Verve Therapeutics for up to $1.3 billion, with shares of Verve Therapeutics increasing 75% in pre-market trading.
The acquisition will provide Eli Lilly with Verve Therapeutics' gene-editing therapy for high cholesterol, with the treatment being evaluated in a Phase 1b clinical trial study.
The deal includes a contingent value right (CVR) per share that entitles holders to $3 per share, subject to the completion of certain milestones.

Generated by AI

Community

Of the messages about VERV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	61.4%
Newcomers	100%	100%	100%	38.6%

Regulars· Jun 15

Verve Therapeutics, Inc. has partnered with Eli Lilly and Company on a gene editing therapy for heart disease, with Lilly providing $60 million in upfront payments and Verve eligible for up to $465 million in milestone payments.
The partnership will focus on developing a new Rx option for patients with elevated Lp(a), a key area of expertise for Verve's Dr. Ruth Gimeno and team.
Verve's market capitalization has taken a hit, with the company giving away one of its three main assets to Lilly for $60 million, and some analysts are skeptical about the partnership's potential success, citing Verve's struggling PCSK9 program.

Newcomers· Nov 8

Verve Therapeutics' stock price dropped 26.33% on Monday due to the FDA halting plans to test the company's gene editor in people.
Verve Therapeutics reported a sales figure of $0.929 million in the fiscal time-frame closing September 30, 2022.
The FDA is expected to provide details to Verve Therapeutics in the next month, which may lead to the opening of enrollment for patients with genetically high cholesterol.

Generated by AI

News

Scribe’s Genetic Editing Aims to Prevent Heart Attacks

2mo agoBarron's

Also Discussed

Investors talking about VERV also mention

#	Name	Attention
1	Beam Therapeutics IncBEAM	0.02%+0.02
2	Intellia Therapeutics, Inc.NTLA	0%+0
3	Prime Medicine, Inc.PRME	0%-0.01
4	Caribou Biosciences, Inc.CRBU	0%new
5	Century Therapeutics IncIPSC	0%0
6	Editas Medicine, Inc.EDIT	0%+0
7	CRISPR Therapeutics AGCRSP	0%-0.01
8	Alnylam Pharmaceuticals, Inc.ALNY	0%0
9	Vertex Pharmaceuticals Incorporated Common StockVRTX	0%-0.01
10	Metagenomi Therapeutics, Inc.MGX	0%0

Verve Therapeutics, Inc.

Location

Social

What share of all stock conversation is about VERV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Jun 18

Eli Lilly's acquisition of Verve Therapeutics, Inc. (VERV) has put the spotlight on other gene therapy companies, including VERVE-102, an investigational therapy aimed at reducing cholesterol levels.
Verve Therapeutics' (VERV) shares have been impacted by the acquisition, with some analysts setting a target price of $13.5, while others have adjusted their rating to Hold.
The acquisition has sparked discussions about the potential for a short squeeze in Verve Therapeutics' (VERV) shares, with some analysts suggesting that the company's shares may be undervalued compared to its peers.

Generated by AI

Sentiment

Of the messages about VERV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	86.81% +0.06
Bearish	—	0%	0% 0	13.19% -0.06

Bullish· Jun 17

$VERV is likely to be acquired, potentially for a price that would result in a significant increase in its market value, with some predictions as high as $10 billion.
The upcoming data from Verve Therapeutics could attract strategic interest, potentially leading to a buyout or acquisition.
$VERV has a game-changing pipeline for heart disease, which could lead to significant growth and value creation for the company.

Bearish· Jun 17

The acquisition price of $1.3 billion may be too low, with some investors demanding at least $3 billion in cash.
The deal may have been undervalued, with some investors believing the company is worth $25 per share.
The acquisition may have been negotiated with insider interests in mind, potentially leaving other shareholders with lower returns.

Generated by AI

Topics

Of the messages about VERV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	1.83%
Announcements	—	—	100%	92.93%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	5.24%

Jun 17

Eli Lilly agreed to acquire Verve Therapeutics for up to $1.3 billion, with shares of Verve Therapeutics increasing 75% in pre-market trading.
The acquisition will provide Eli Lilly with Verve Therapeutics' gene-editing therapy for high cholesterol, with the treatment being evaluated in a Phase 1b clinical trial study.
The deal includes a contingent value right (CVR) per share that entitles holders to $3 per share, subject to the completion of certain milestones.

Generated by AI

Community

Of the messages about VERV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	61.4%
Newcomers	100%	100%	100%	38.6%

Regulars· Jun 15

Verve Therapeutics, Inc. has partnered with Eli Lilly and Company on a gene editing therapy for heart disease, with Lilly providing $60 million in upfront payments and Verve eligible for up to $465 million in milestone payments.
The partnership will focus on developing a new Rx option for patients with elevated Lp(a), a key area of expertise for Verve's Dr. Ruth Gimeno and team.
Verve's market capitalization has taken a hit, with the company giving away one of its three main assets to Lilly for $60 million, and some analysts are skeptical about the partnership's potential success, citing Verve's struggling PCSK9 program.

Newcomers· Nov 8

Verve Therapeutics' stock price dropped 26.33% on Monday due to the FDA halting plans to test the company's gene editor in people.
Verve Therapeutics reported a sales figure of $0.929 million in the fiscal time-frame closing September 30, 2022.
The FDA is expected to provide details to Verve Therapeutics in the next month, which may lead to the opening of enrollment for patients with genetically high cholesterol.

Generated by AI

Verve Therapeutics

Verve Therapeutics, Inc.

Company Information

Location

Verve Therapeutics

Social

Jun 18

Sentiment

Bullish· Jun 17

Bearish· Jun 17

Topics

Jun 17

Community

Regulars· Jun 15

Newcomers· Nov 8

News

Scribe’s Genetic Editing Aims to Prevent Heart Attacks

Also Discussed

Verve Therapeutics, Inc.

Company Information

Location

Social

Jun 18

Sentiment

Bullish· Jun 17

Bearish· Jun 17

Topics

Jun 17

Community

Regulars· Jun 15

Newcomers· Nov 8

News

Scribe’s Genetic Editing Aims to Prevent Heart Attacks

Also Discussed